Abstract
Rheumatoid arthritis is a chronic disorder for which there is no known cure. Concentrating on specific elements of the abnormal immune response that characterizes the disease, scientists are reaching into biotechnology's bag of tricks to develop immunotherapeutic techniques. This paper will present some advances in the immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antigens, CD / therapeutic use
-
Arthritis, Rheumatoid / immunology*
-
Arthritis, Rheumatoid / therapy*
-
CTLA-4 Antigen
-
Collagen Type II / therapeutic use
-
Cytokines / immunology
-
Humans
-
Immune Tolerance
-
Immunotherapy*
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / transplantation
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Collagen Type II
-
Cytokines